Record-High Patient Impact
In 2024, OrthoPediatrics helped over 138,000 kids, a record high for the company, marking significant growth in patient impact.
Revenue and Growth Metrics
Total revenue for Q4 2024 was $52.7 million, representing a 40% growth from the comparable period. The full-year revenue expectation for 2025 is between $235 to $242 million, an annual growth of 15% to 18%.
Significant Growth in Key Segments
TMD and scoliosis segments saw quarterly growth of 35% and 62%, respectively. The scoliosis global revenue increased by 62% compared to the prior year.
Adjusted EBITDA Improvement
Adjusted EBITDA more than doubled in Q4 2024 to $3.0 million, with an expectation of $15 to $17 million in adjusted EBITDA for 2025.
Positive Free Cash Flow Projection
The company expects to achieve its first quarter of positive free cash flow by Q4 2025.
Expansion and Integration Success
Successful integration of Boston OMP and expansion of the OPSB business, with plans for four new territories in 2025.
Strong International Demand
Despite challenges, EMEA T&D growth was strong due to high demand, and non-LATAM T&D growth exceeded 20% with scoliosis growing nearly 30%.
New Product Launches and R&D Advancements
Launches included PMP Tibia and DF2 femur fracture brace, with plans for a beta launch of the 3P hip system and new EOS products.